IN THE CLAIMS

This listing of claims replaces all prior versions, and listings, in this application.

1. (currently amended) A compound of formula (I) with an optional label:

cyclo [NX_1-R_1-CO-NX_2-R_2-CO-NX_3-R_3-CO-NX_4-R_4-CO-NX_5-R_5-CO] wherein

~~where:~~ R_1 is selected from the group consisting of[[:]] $CH(CH_2)_3NHC(NH)NH_2$ and $C[CH_nF_m](CH_2)_3NHC(NH)NH_2$;

R_2 is selected from the group consisting of $CH_{2,}$ [[and]] CH_2-$CH_{2,}$ [[:]]



[[:]] and



;

R_3 is selected from the group consisting of $CHCH_2COOH$ and $C[CH_nF_m]CH_2$-COOH;

R_4 is selected from the group consisting of CH-CH_2-$Ph_{,}$ [[:]] $C[CH_nF_m]CH_2$-$Ph_{,}$ [[:]] CH-CH_2-(4-OH)$Ph_{,}$ [[:]] CH-CH_2-(4-OMe)$Ph_{,}$ [[:]] CH-CH_2-(4-F)$Ph_{,}$ [[:]] CH-CH(OH)-$Ph_{,}$ [[:]] $C(CH_3)_{2,}$ [[:]] CH-$C(CH_3)_{3,}$ ~~; and~~ CH-CH_2-COOH [[:]] and



;

R_5 is selected from the group consisting of CH-CH_2-$Ph_{,}$ [[:]] $C[CH_nF_m]CH_2$-$Ph_{,}$ [[:]] CH-$CH(CH_3)_{2,}$ [[:]] $C[CH_nF_m]CH(CH_3)_2$ [[:]] and CH-$C(CH_3)_3$;

or [[,]] the group NX_4-R_4-CO-NX_5-R_5-CO is 3-aminomethyl-benzoyl;

n + m = 3;

X_1-X_5, which may be the same or different, are H, [[or]] $(CH_2)_b$-$CH_{3,}$[[:]]



$(CH_2)_p$-CHF_2 [[;]] $(CH_2)_p$-CH_2F [[,]] or $(CH_2)_p$-CF_3 where p = 0-3;
with the proviso that there is at least one α-fluoroalkylated amino acid present in the formula (I) compound;
where each NX-R-CO amino acid can have an absolute type R or type S configuration; their individual enantiomers, diastereoisomers, [[the]] related mixtures, or [[the]] pharmaceutically acceptable salts.

2. (previously presented) The compound according to claim 1, selected from the group consisting of:

c (Arg-Gly-Asp-D-Phe-(*R or S*)-Tfm-Phe);
c (Arg-Gly-Asp-D-Phe-(*R, S*)-Dfm-Phe);
c (Arg-Gly-Asp-(*R or S*)-Tfm-Phe-Val) (SEQ ID NO:1);
c (Arg-Gly-Asp-D-Phe-(*R or S*)-Tfm-Val) and
c (Arg-Gly-Asp-D-Phe-(*R or S*)-N-Me-Tfm-Phe.

3. (previously presented) A method of inhibiting receptors belonging to the family of the integrins belonging to the $\alpha_v\beta_3$ and $\alpha_v\beta_5$ system in a human, said method comprising administering a compound according to claim 1 to said human in a manner whereby said receptors are inhibited.

4. (previously presented) A method of preparing a medicament comprising admixing a compound of claim 1 with a pharmaceutically acceptable vehicle or excipient.

5. (previously presented) The method of claim 3 wherein angiogenic activity of said human is inhibited.

6. (previously presented) The method of claim 3 wherein metastatic activity of said human is inhibited.

7. (previously presented) The method of claim 3 wherein said human has disease selected from the group consisting of retinopathy, acute kidney failure, and osteoporosis.

8. (previously presented) Pharmaceutical compositions containing at least one compound according to claim 1 as an active ingredient in a mixture with pharmaceutically acceptable vehicles and/or excipients.

Claim 9 (canceled)

10. (previously presented) A compound of claim 1 further comprising a label.

11. (previously presented) A method of detecting the location of a tumor in a human comprising administering to said human a compound of claim 10 and detecting said label in said human in a manner whereby the location of said tumor is detected.

12. (previously presented) The method of claim 11 wherein said tumor is a small tumor mass.

13. (previously presented) A method of detecting the location of an arterial occlusion in a human comprising administering to said human a compound of claim 10 and detecting said label in said human in a manner whereby the location of said arterial occlusion is detected.

14. (previously presented) The method of claim 13 wherein said arterial occlusion is the result of a stroke or myocardial infarct.

Claim 15 (canceled)